FrancophonIA/ELRC3.0 huggingface dataset:
English: Common serious side effects (may affect up to 1 in 10 people): - Loss of appetite - Dehydration - Reduction in red blood cells (anaemia) - Decreased blood levels of calcium and sodium - A very fast heart beat - High or low blood pressure - Abdominal pain accompanied by difficulty or blockage passing stools, constipation - Shortness of breath - Accumulation of fluid around the lungs which cause chest pain and breathlessness - Inflammation of the bile ducts - Skin redness, rash - Very fast heartbeat, fever, shortness of breath, feeling faint or light-headed - Complex of reactions due to the release of mediators of inflammation - Worsening of general state of health, generally feeling unwell and weak - Fluid retention - Hypersensitivity
Maltese: - Nuqqas ta' aptit - Deidratazzjoni - Tnaqqis fl-għadd ta' ċelluli ħomor tad-demm (anemija) - Tnaqqis fil-livelli ta' kalċju u sodju - Taħbit tal-qalb mgħaġġel ħafna - Pressjoni tad-demm għolja jew baxxa - Uġigħ addominali akkompanjat minn diffikultà jew imblokk biex tipporga, stitikezza - Qtugħ ta' nifs - Akkumulazzjoni ta' fluwidu madwar il-pulmun li tikkawża wġigħ fis-sider u qtugħ ta' nifs - Infjammazzjoni tal-kanali tal-bila - Ħmura tal-ġilda, raxx - Taħbit tal-qalb mgħaġġel ħafna, deni, qtugħ ta' nifs, ħass ħażin jew mejt.
English: Systemic Inflammatory Response Syndrome (SIRS), which may also occur commonly due to the mechanism of action of catumaxomab, develops, in general, within 24 hours after Removab infusion, showing symptoms of fever, tachycardia, tachypnoea and leucocytosis (see section 4.8).
Maltese: Is-Sindrome tar-Rispons Infjammatorju Sistemiku (SIRS), li jista' jseħħ ukoll b'mod komuni minħabba l-mekkaniżmu tal-azzjoni ta' catumaxomab, jiżviluppa, b'mod ġenerali, fi żmien 24 siegħa wara l-infużjoni ta' Removab, u jkun hemm sintomi ta' deni, takikardija, takipnea u lewkoċitosi (ara sezzjoni 4.8).
English: Cytokine-release related reactions: SIRS a potentially life-threatening combination of tachycardia, fever and/or dyspnoea, can develop within 24 hours after a catumaxomab infusion and resolves under symptomatic treatment.
Maltese: Reazzjonijiet relatati ma' ħruġ ta' cytokines: SIRS, taħlita potenzjalment fatali ta' takikardija, deni u/jew qtugħ ta' nifs, jistgħu jiżviluppaw fi żmien 24 siegħa wara infużjoni ta' catumaxomab u tissolva taħt kura sintomatika.
English: Breast
Maltese: Varjabbli
English: One pre-filled syringe contains 10 micrograms catumaxomab in 0.1 ml solution, corresponding to 0.1 mg/ml.
Maltese: U KWANTITATTIVA Siringa mimlija għal-lest fiha 10 mikrogrammi ta' catumaxomab* f'soluzzjoni ta' 0.1 ml li tikkorrispondi għal 0.1 mg/ml.
English: The composite safety score evaluated the frequency and severity of the main known adverse reactions pyrexia, nausea, vomiting and abdominal pain in both treatment groups.
Maltese: Il-punteġġ tas-siġurtà komposta evalwa l-frekwenza u s-severità tar-reazzjonijiet avversi ewlenin, deni, tqalligħ, rimettar u wġigħ addominali fiż-żewġ gruppi ta' kura.
English: 4th infusion 150 micrograms
Maltese: 150 mikrogramma
English: NAME OF THE MARKETING AUTHORISATION HOLDER Neovii Biotech GmbH
Maltese: DETENTUR TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ Neovii Biotech GmbH
English: • The pre-filled syringe cannula is inserted through the 50 ml syringe opening so that the cannula is immersed in the sodium chloride 9 mg/ml (0.9%) solution for injection (Figure 2).
Maltese: • Il-kannula tas-siringa mimlija għal-lest tiddaħħal minn ġol-ftuħ tas-siringa tal-perfużjoni ta' 50 ml biex b'hekk il-kannula tkun mgħaddsa fis-soluzzjoni għall-injezzjoni tas-sodium chloride 9 mg/ml (0.9%) (Figura 2).
English: Uncommon serious side effects (may affect up to 1 in 100 people): - Lumps under the skin on the back of the legs that may become sores and leave scars - Inflammation and pain or burning and stinging in the area around the catheter - Reduction in number of blood platelets, blood clotting problems - Bleeding in the stomach or gut, shown by the vomiting of blood or the passage of red or black stools - Skin reaction, severe allergic skin reaction (dermatitis) - Fits - Lung problems including blood clot in the lungs - Low blood oxygen levels - Severe kidney problems - Extravasation (inadvertent leakage of administered medicinal product from the intraperitoneal catheter system into surrounding tissue)
Maltese: - Nefħiet taħt il-ġilda fuq in-naħa ta' wara tar-riġlejn li jistgħu jiżviluppaw f'feriti u jħallu ċikatriċi - Infjammazzjoni u wġigħ jew ħruq u tingiż fiż-żona madwar il-kateter - Tnaqqis fin-numru ta' plejtlits fid-demm, problemi bl-emboli tad-demm - Ħruġ ta' demm fl-istonku jew fl-imsaren, muri bir-rimettar ta' demm jew li tagħmel ippurgar aħmar jew iswed - Reazzjoni tal-ġilda, reazzjoni allerġika severa tal-ġilda (dermatite) - Aċċessjonijiet - Problemi fil-pulmun li jinkludu embolu tad-demm fil-pulmun - Livelli baxxi ta' ossiġnu fid-demm - Problemi serji tal-kliewi - Extravażazzjoni (tnixxija aċċidentali tal-prodott mediċinali, mogħti mis-sistema tal-kateter ġol-peritonew, għal ġot-tessut tal-madwar)
English: oedema peripheral*, general physical health deterioration*, chest pain, influenza-like illness, malaise*, catheter site erythema.
Maltese: Uġigħ, astenja*, Sindrome tar-rispons infjammatorju sistemiku*, edema li tinkludi edema periferali*, deterjorament ġenerali tas-saħħa fiżika*, uġigħ fis-sider, marda qisha influwenza, telqa*, eritema fis-sit tal-kateter.
English: *rat-mouse hybrid IgG2 monoclonal antibody produced in a rat-mouse hybrid-hybridoma cell line For the full list of excipients, see section 6.1.
Maltese: • Il-lasta tal-planġer M'GĦANDHIEX tinġibed lura biex tlaħlaħ is-siringa mimlija għal-lest, biex tevita l-kontaminazzjoni u biex tiżgura li joħroġ l-ammont li suppost ikun injettat.
English: Transient increase in hepatic enzymes was commonly observed after the administration of Removab.
Maltese: Żieda temporanja fl-enzimi epatiċi kienet komunament osservata wara l-għoti ta' Removab.
English: Patients with hepatic impairment of a higher severity grade than moderate and / or with more than 70% of the liver metastasised and / or portal vein thrombosis / obstruction have not been investigated.
Maltese: Pazjenti b' indeboliment epatiku ta' severità ogħla minn moderata u/jew b'iktar minn 70% tal-fwied li jkun metastasizzat u/jew bi trombożi/ostruzzjoni tal-vina portali, ma kinux investigati.
English: A pivotal, two-arm, randomised, open-label, phase II/III clinical trial in 258 patients with symptomatic malignant ascites due to EpCAM-positive carcinomas of whom 170 were randomised to catumaxomab treatment.
Maltese: II/III, b'żewġ partijiet, li fih il-parteċipanti ntgħażlu b'mod każwali, open label, li saret fuq 258 pazjent b'axxite malinna sintomatika minħabba karċinomi pożittivi għal EpCAM, li minnhom 170 kienu ntgħażlu b'mod każwali għall-kura b'catumaxomab fil-parti talistudju li fiha ntgħażlu b'mod każwali.
English: Talk to your doctor or nurse before using Removab.
Maltese: Kellem lit-tabib jew l-infermier tiegħek qabel ma tuża Removab.
English: Sodium chloride 9 mg/ml (0.9%) solution for injection
Maltese: 1 250 ml Sodium Chloride 9 mg/ml (0.9%) 2 Soluzzjoni ta' Removab għal infużjoni i.p.
English: Table 5 Efficacy results (puncture-free survival and time to first need for therapeutic ascites puncture) of study IP-CAT-AC-03
Maltese: Riżultati tal-effikaċja (sopravivenza mingħajr titqib u ż-żmien għall-ewwel ħtieġa ta' titqiba terapewtika tal-axxite) ta' studju IP-CAT-AC-03
English: Time (days) to event
Maltese: Żmien (jiem) għall-avveniment
English: NAME OF THE MEDICINAL PRODUCT Removab 50 micrograms concentrate for solution for infusion catumaxomab
Maltese: Removab 50 mikrogramma konċentrat għal soluzzjoni għall-infużjoni catumaxomab
English: Read the package leaflet before use.
Maltese: Perċentwali ta' effużjonijiet pożittivi ta'
English: Precautions to be taken before administering the medicinal product Before administration of Removab the concentrate for solution for infusion is diluted in sodium chloride 9 mg/ml (0.9%) solution for injection.
Maltese: Prekawzjonijiet li għandhom jittieħdu qabel tamministra l-prodott mediċinali Qabel l-għoti, Removab konċentrat għal soluzzjoni għall-infużjoni jkun dilwit f'soluzzjoni għallinjezzjoni ta' 9 mg/ml (0.9%) ta' sodium chloride.
English: 3rd dose
Maltese: Wara d-dilwizzjoni
English: As secondary efficacy endpoint overall survival (Table 6) was assessed.
Maltese: Għal punt aħħari ta' riferiment għall-effikaċja sekondarja, is-sopravivenza globali (Tabella 6) ġiet analizzata
English: Cholangitis*, hyperbilirubinaemia.
Maltese: Użu għal ġol-peritonew biss, wara d-dilwizzjoni.
English: Patients with renal impairment of a higher severity grade than mild have not been investigated.
Maltese: Pazjenti b'indeboliment renali ta' severità ogħla minn ħafifa ma kinux investigati.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One pre-filled syringe contains 10 micrograms of catumaxomab* in 0.1 ml solution, corresponding to 0.1 mg/ml.
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) Siringa mimlija għal-lest fiha 10 mikrogrammi ta' catumaxomab* f'soluzzjoni ta' 0.1 ml, li tikkorrispondi għal 0.1 mg/ml.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Maltese: Jekk ma jintużax immedjatament, iż-żmien tal-ħażna waqt l-użu u l-kundizzjonijiet ta' qabel l-użu huma r-responsabbiltà tal-utent, u normalment ma jkunux itwal minn 24 siegħa f'temperatura ta' minn 2 sa 8°C, sakemm id-dilwizzjoni ma tkunx saret f'kundizzjonijiet asettiċi kkontrollati u vverifikati.
English: (Groups A, B, C and G)
Maltese: (Gruppi A, B, Ċ u G)
English: • The baby is premature.
Maltese: • It-tarbija hija prematura.
English: Streptococcus pyogenes (Group A) Streptococcus agalactiae (Group B) Streptococcus pneumoniae Viridans Group Streptococci
Maltese: Streptococcus pyogenes (Grupp A) Streptococcus agalactiae (Grupp B) Streptococcus pneumoniae Streptococci tal-grupp Virdans
English: Do not mix with solutions that contain calcium, including Hartmann's, Ringers and Total Parenteral Nutrition
Maltese: Tħallatx ma' soluzzjonijiet li fihom il-kalċju, inkluż Hartmann's, Ringers u Nutrizzjoni Parenterali Totali
English: • to prevent infections during surgery.
Maltese: • biex jiġu evitati infezzjonijiet waqt kirurġija.
English: See section 4.4
Maltese: b Ara sezzjoni 4.4
English: Each gram of Rocephin contains 3.6 mmol sodium.
Maltese: Kull gramma ta' Rocephin fiha 3.6 mmol ta' sodium.
English: Syphilis
Maltese: Sifilide
English: Moraxella catarrhalis Neisseria gonorrhoeae Neisseria meningitidis
Maltese: Neisseria gonorrhoeae Neisseria meningitidis ċ.
English: Common (≥ 1/100 - < 1/10)
Maltese: Komuni (≥ 1/100 - < 1/10)
English: The following convention has been used for the classification of frequency:
Maltese: Il-konvenzjoni li ġejja ntużat għall-klassifikazzjoni tal-frekwenza:
English: Rocephin is usually given by a doctor or nurse.
Maltese: Rocephin normalment jingħata minn tabib jew infermier.
English: Dilution Test (MIC, mg/L)
Maltese: Test tad-Dilwazzjoni (MIC, mg/L) Suxxettibbli
English: • A type of antibiotic called an aminoglycoside.
Maltese: • Tip ta' antibijotiku imsejjaħ aminoglycoside.
English: • Oedema (fluid build-up).
Maltese: • Edima (akkumulazzjoni ta' fluwidu).
English: Erythema multiforme Acute generalised exanthematous pustulosis
Maltese: Eritema multiforme Exanthematous pustulosis ġeneralizzata akuta
English: Stevens Johnson Syndromeb
Maltese: Sindrome ta' Stevens Johnsonb
English: • Dizziness.
Maltese: • Konvulżjonijiet.
English: • outer membrane impermeability in Gram-negative organisms.
Maltese: • impermeabbiltà tal-membrana ta' barra f'organiżmi negattivi għal Gram.
English: Biliary stasis
Maltese: Stasi biljari
English: Streptococcus pneumoniae
Maltese: Streptococcus pneumoniae ċ.
English: the abdomen and abdominal wall (peritonitis).
Maltese: • addome u ħajt addominali (peritonite).
English: • Inflammation of the tongue (glossitis).
Maltese: • Infjammazzjoni tal-ilsien (glossite).
English: Staphylococcus aureus (methicillin-susceptible)£ Staphylococci coagulase-negative (methicillin-susceptible)£
Maltese: Staphylococcus aureus (suxxettibli għal methicillin) £ Staphylococci negattivi għal coagulase (suxxettibli għal methicillin) £
English: Disseminated Lyme borreliosis (early [Stage II] and late [Stage III]) 50-80 mg/kg once daily for 14-21 days.
Maltese: Lyme borreliosis mifruxa (bikrija [Stadju II] u ttardjata [Stadju III]) 50 - 80 mg/kg darba kuljum għal 14-21 ġurnata.
English: Plasma clearance of total ceftriaxone (bound and unbound) is 10 - 22 ml/min.
Maltese: Tneħħija mill-plażma ta' ceftriaxone totali (imwaħħal u mhux imwaħħal) hija ta' 10 - 22 ml/min.
English: After intravenous infusion of ceftriaxone 500 mg, 1 g and 2 g, the plasma ceftriaxone levels are approximately 80, 150 and 250 mg/l respectively.
Maltese: Wara infużjoni fil-vini ta' 500 mg, 1 g u 2 g ceftriaxone, il-livelli fil-plażma ta' ceftriaxone huma madwar 80, 150 u 250 mg/l rispettivament.
English: • Form of anaemia where red blood cells are destroyed (haemolytic anaemia).
Maltese: • Forma ta' anemija fejn ċelluli ħomor tad-demm jiġu meqruda (anemija emolitika).
English: • reduced affinity of penicillin-binding proteins for ceftriaxone.
Maltese: • affinità mnaqqsa ta' proteini li jeħlu ma' penicillin għal ceftriaxone.
English: • 1 to 2 g once a day depending on the severity and type of infection.
Maltese: • 1 sa 2 g darba kuljum skont is-severità u t-tip ta' infezzjoni.
English: Use of lidocaine
Maltese: Użu ta' lidocaine
English: Ceftriaxone is not metabolised systemically; but is converted to inactive metabolites by the gut flora.
Maltese: Ceftriaxone mhux metabolizzat b'mod sistemiku; iżda jiġi mibdul għall-metaboliti inattivi mill-flora tal-imsaren.
English: Precipitation is usually reversible upon discontinuation of ceftriaxone (see section 4.4).
Maltese: Preċipitazzjoni normalment hija riversibbli mat-twaqqif ta' ceftriaxone (ara sezzjoni 4.4).
English: • Shivering.
Maltese: • Sturdament.
English: In an in-vitro study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone.
Maltese: Fi studju in vitro kienu osservati effetti antagonistiċi bit-taħlita ta' chloramphenicol u ceftriaxone.
English: In symptomatic cases, sonography should be performed.
Maltese: F'każijiet sintomatiċi, għandha ssir sonografija.
English: Uncommon (≥ 1/1000 - < 1/100) Rare (≥ 1/10000 - < 1/1000)
Maltese: Rari (≥ 1/10000 - < 1/1000)
English: • Inflammation of the pancreas (pancreatitis).
Maltese: • Infjammazzjoni tal-frixa (pankreatite).
English: Treatment frequency**
Maltese: Frekwenza talkura **
English: Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosaemia.
Maltese: Ceftriaxone, bħal antibijotiċi oħra, jista' jwassal għal testijiet pożittivi foloz għal galaktosemija.
English: ceftriaxone (as ceftriaxone sodium)
Maltese: ceftriaxone (bħala ceftriaxone sodium)
English: Based on literature reports, ceftriaxone is not compatible with amsacrine, vancomycin, fluconazole and aminoglycosides.
Maltese: Ibbażat fuq rapporti mil-letteratura, ceftriaxone mhux kompatibbli ma' amsacrine, vancomycin, fluconazole u aminoglycosides.
English: Borrelia burgdorferi Haemophilus influenzae Haemophilus parainfluenzae Moraxella catarrhalis Neisseria gonorrhoea Neisseria meningitidis Proteus mirabilis Providencia spp.
Maltese: Neisseria gonorrhoea Neisseria meningitidis Proteus mirabilis Providencia spp Treponema pallidum
English: • A false positive result for galactosaemia (an abnormal build up of the sugar galactose).
Maltese: • Riżultat pożittiv falz għal galaktosemija (akkumulazzjoni mhux normali taz-zokkor galactose).
English: the lungs.
Maltese: • pulmun.
English: • to treat infections of the chest in adults with chronic bronchitis.
Maltese: • biex jikkura infezzjonijiet fis-sider f'adulti bi bronkite kronika.
English: Intravenous intermittent injection should be given over 5 minutes preferably in larger veins.
Maltese: Injezzjoni intermittenti fil-vini għandha tingħata fuq medda ta' 5 minuti preferibbilment filvini l-kbar.
English: In older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.
Maltese: F'persuni anzjani li għandhom aktar minn 75 sena l-half-life medja tal-eliminazzjoni normalment hija darbtejn jew tliet darbiet dik ta' adulti żgħażagħ.
English: • A high temperature (fever).
Maltese: • Temperatura għolja (deni).
English: You may be given a different dose to the usual dose.
Maltese: Inti tista' tingħata doża differenti mid-doża normali.
English: Pancreatitisb Stomatitis Glossitis
Maltese: Pankreatiteb Stomatite Infjammazzjoni tal-ilsien
English: An immune mediated haemolytic anaemia has been observed in patients receiving cephalosporin class antibacterials including Rocephin (see section 4.8).
Maltese: Anemija emolitika medjata mill-immunità Anemija emolitika medjata mill-immunità kienet osservata f'pazjenti li kienu qed jirċievu antibatteriċi tal-klassi cephalosporin inkluż Rocephin (ara sezzjoni 4.8).
English: The incidence appears to be lower with slow infusion (20 - 30 minutes).
Maltese: L-inċidenza tidher li hija aktar baxxa b'infużjoni bil-mod (fuq 20 - 30 minuta).
English: • An antibiotic called chloramphenicol (used to treat infections, particularly of the eyes).
Maltese: • Antibijotiku msejjaħ chloramphenicol (użat biex jikkura infezzjonijiet, speċjalment talgħajnejn).
English: • bacterial efflux pumps.
Maltese: • pompi ta' effluss fil-batterja.
English: Concentrations for the intravenous injection: 100 mg/ml, Concentrations for the intravenous infusion: 50 mg/ml (Please refer to section 4.2 for further information).
Maltese: Konċentrazzjonijiet għall-infużjoni fil-vini: 50 mg/ml (Jekk jogħġbok irreferi għal sezzjoni 4.2 għal aktar informazzjoni).
English: 100 mg/kg (max 4 g)
Maltese: 100 mg/kg (massimu 4 g)
English: Newborn babies (0-14 days)
Maltese: Trabi tat-twelid (0-14-il ġurnata)
English: An 8 - 15 % increase in mean peak plasma concentration (Cmax) is seen on repeated administration; steady state is reached in most cases within 48 - 72 hours depending on the route of administration.
Maltese: Żieda ta' 8 - 15 % fil-konċentrazzjoni massima medja fil-plażma (Cmax) tkun osservata wara għoti ripetut; fil-biċċa l-kbira tal-każijiet stat fiss jintlaħaq fi żmien 48 - 72 siegħa skont ir-rotta tal-għoti.
English: • You have recently had diarrhoea after having an antibiotic medicine.
Maltese: • Dan l-aħħar kellek dijarea wara li ħadt mediċina antibijotika.
English: Rocephin may be used:
Maltese: Rocephin jista' jintuża:
English: 500 mg Powder and Solvent for Solution for Injection Denmark, Finland: Rocephalin
Maltese: 500 mg Trab u Solvent għal Soluzzjoni għall-Injezzjoni Id-Danimarka, il-Finlandja:
English: There are no study data in patients with severe hepatic impairment (see section 5.2).
Maltese: M'hemmx dejta minn studji f'pazjenti b'indeboliment epatiku sever (ara sezzjoni 5.2).
English: Rocephin can also lead to false-positive test results for galactosaemia (see section 4.8).
Maltese: Rocephin jista' jwassal ukoll għal riżultati pożittivi foloz tat-test għal galaktosemija (ara sezzjoni 4.8).
English: Adults and children over 12 years of age (≥ 50 kg)
Maltese: Adulti u tfal b'età 'l fuq minn 12-il sena (≥ 50 kg)
English: 80-100 mg/kg (max 4 g)
Maltese: 80-100 mg/kg (massimu 4 g)
English: Kernicterus
Maltese: Bijotrasformazzjoni
English: 250 mg, 500 mg, 1 g powder and solvent for solution for injection 250 mg powder for solution for injection 1 g powder for solution for injection or infusion 2 g powder for solution for injection or infusion Intravenous or intramuscular use
Maltese: 250 mg, 500 mg, 1 g trab u solvent għal soluzzjoni għall-injezzjoni 250 mg trab għal soluzzjoni għall-injezzjoni 1 g trab għal soluzzjoni għall-injezzjoni jew infużjoni 2 g trab għal soluzzjoni għall-injezzjoni jew infużjoni Użu għal ġol-vini jew għal ġol-muskoli
English: 250 mg, 500 mg, 1 g powder and solvent for solution for injection Powder and solvent for solution for injection [To be completed nationally]
Maltese: 250 mg, 500 mg, 1 g trab u solvent għal soluzzjoni għall-injezzjoni
English: • A false positive result in a Coombs' test (a test for some blood problems).
Maltese: • Riżultat pożittiv falz tat-test ta' Coombs (test għal xi problemi fid-demm).
English: Urine glucose determination during therapy with Rocephin should be done enzymatically (see section 4.8).
Maltese: Determinazzjoni ta' glucose fl-awrina waqt terapija b'Rocephin għandha ssir b'mod enzimatiku (ara sezzjoni 4.8).
English: • You are on a low sodium diet.
Maltese: • Inti fuq dieta ta' sodium baxx.
English: Severe cutaneous adverse reactions (Stevens Johnson syndrome or Lyell's syndrome/toxic epidermal necrolysis) have been reported; however, the frequency of these events is not known (see section 4.8).
Maltese: Reazzjonijiet avversi severi fil-ġilda (sindrome Stevens Johnson jew sindrome ta' Lyell/nekrolisi tossika tal-epidermide) kienu rrappurtati; madankollu, il-frekwenza ta' dawn l-avvenimenti mhix magħrufa (ara sezzjoni 4.8).
English: Gram-negative aerobes
Maltese: Aerobiċi negattivi għal Gram
English: For Pre-operative prophylaxis of surgical site infections
Maltese: Profilassi qabel kirurġija ta' infezzjonijiet fis-sit ta' kirurġija
English: There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (intravenous or oral).
Maltese: Ma kienx hemm rapporti ta' interazzjoni bejn ceftriaxone u prodotti orali li fihom il-kalċju jew interazzjoni bejn ceftriaxone fil-muskoli u prodotti li fihom il-kalċju (fil-vini jew orali).
English: Ceftriaxone dosage*
Maltese: Ceftriaxone*
English: The high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2).
Maltese: Ir-riskju għoli ta' preċipitazzjoni fi trabi tat-twelid huwa riżultat talvolum baxx ta' demm tagħhom u l-half-life itwal ta' ceftriaxone meta mqabbla mal-adulti (ara sezzjonijiet 4.3, 4.4, u 5.2).
English: Plasma protein binding is about 95 % at plasma concentrations below 100 mg/l.
Maltese: madwar 95 % f'konċentrazzjonijiet fil-plażma taħt 100 mg/l.
English: Rocephin 250 mg Powder and Solvent for Solution for Injection Hungary, Portugal: Rocephin
Maltese: Rocephin 250 mg Trab u Solvent għal Soluzzjoni għall-Injezzjoni
English: 50-100 mg/kg (Max 4 g)
Maltese: 50-100 mg/kg (Massimu 4 g)
English: Italy: Rocefin
Maltese: Rocefin
English: • Vertigo (spinning sensation).
Maltese: • Vertigo (sensazzjoni li kollox qed idur bik).
English: However, a risk of diarrhoea and fungal infection of the mucous membranes cannot be excluded.
Maltese: ma jistax jiġi eskluż riskju ta' dijarea u ta' infezzjoni mill-moffa tal-membrani mukużi.
English: Toxic epidermal necrolysisb
Maltese: Nekrolisi tossika talepidermideb
English: • to treat specific sexually transmitted infections (gonorrhoea and syphilis).
Maltese: • biex jikkura infezzjonijiet speċifiċi trasmessi sesswalment (gonorrea u sifilide). .
English: Other medicines and Rocephin
Maltese: Mediċini oħra u Rocephin
English: Reproductive studies have shown no evidence of adverse effects on male or female fertility.
Maltese: Studji dwar ir-riproduzzjoni ma wrew l-ebda evidenza ta' effetti avversi fuq il-fertilità maskili jew femminili.
English: Cases of pancreatitis, possibly of biliary obstruction aetiology, have been reported in patients treated with Rocephin (see section 4.8).
Maltese: Każijiet ta' pankreatite, possibilment b'etjoloġija ta' ostruzzjoni biljari, kienu rrappurtati f'pazjenti kkurati b'Rocephin (ara sezzjoni 4.8).
English: Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs).
Maltese: Ceftriaxone jinibixxi s-sintesi tal-ħajt taċ-ċellula tal-batterja wara twaħħil mal-proteini li jeħlu ma' penicillin (PBPs - penicillin binding proteins).